EUVIMEDEUVIMED entdecken
Systematische Übersicht

A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease

Malindi Georgia Haggett iD, Sangho Lee, Francis Yi Xing Lai

Australasian Journal of Dermatology · 2025

DOI: 10.1111/ajd.14391 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Australasian Journal of Dermatology, 2025. Verfasst von Malindi Georgia Haggett und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The Royal Children's Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: TYK2 Kinase, Protein Kinase Inhibitors, Skin Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study systematically reviews existing data on the efficacy of Tyrosine Kinase 2 (TYK2) inhibitors in comparison to placebo or standard treatments for therapeutic benefit and improving quality of life in dermatological diseases. Seventeen records representing 13 clinical trials, one matching‐adjusted indirect comparison, and one case study were included. Results indicate that Deucravacitinib is superior to placebo, Apremilast and Adalimumab in treating adult patients with moderate‐to‐severe plaque psoriasis and superior to placebo in the treatment of adults with systemic lupus erythematosus. Comparative investigations on Brepocitinib and Ropsacitinib were more limited. Oral Brepocitinib demonstrated superiority over placebo in managing alopecia areata, and hidradenitis suppurativa. Topical Brepocitinib exhibited superiority over placebo in treating atopic dermatitis, but not plaque psoriasis. Ropsacitinib demonstrated superiority over placebo in the management of plaque psoriasis. Brepocitinib and Ropsacitinib had more side effects than Deucravacitinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TYK2 KinaseProtein Kinase InhibitorsSkin DiseasesHumansPsoriasis

Stichwörter der Autor:innen

TYK2 inhibitordermatologydeucravacitinibskin disease

Substanzen

TYK2 KinaseProtein Kinase InhibitorsTYK2 protein, human

Autor:innen und Institutionen

  • Department of Dermatology, The Royal Children's Hospital, Melbourne, Victoria, Australia.
  • Department of Dermatology, Monash Medical Centre, Melbourne, Victoria, Australia.
  • Department of Dermatology, Skin Health Institute, Melbourne, Victoria, Australia.

ORCID-Profile: Malindi Georgia Haggett

Zitieren

APA

Haggett, M. G., Lee, S., & Lai, F. Y. X. (2025). A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14391

Vancouver

Haggett MG, Lee S, Lai FYX. A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease. Australasian Journal of Dermatology. 2025. doi:10.1111/ajd.14391

BibTeX
@article{Haggett2025,
  author = {Haggett, Malindi Georgia and Lee, Sangho and Lai, Francis Yi Xing},
  title = {A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease},
  journal = {Australasian Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ajd.14391}
}
Kostenlos starten →